Prexton Therapeutics has the mission to develop innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other brain disorders. Prexton Therapeutics has the expertise to design novel mGluR4 compounds as new treatment for Parkinson’s disease.
Learn MoreRecent Events
Bioequity Europe 2013 in Stock ...
May 22-23, 2013. Francois Conquet CEO of Prexton Therapeutics presented the company durin ...
Learn More
Prexton opts for Parkinson dru ...
23.01.2013 - Merck-Serono spin-out Prexton Therapeutics has secured an exclusive licence o ...
Learn More
J.P. MORGAN HEALTHCARE CONFERE ...
January 7-10, 2013. Prexton Therapeutics will be present at the 31st Annual J.P. Morgan H ...
Learn More
European Parkinson's Disease S ...
November 22, 2011. European Parkinson's Disease Standards of Care Consensus Statement. T ...
Learn MoreLast Press Release
PREXTON THERAPEUTICS ANNOUNCE
January 22, 2013. Prexton Therapeutics will develop novel mGluR4 PAM series, via an ...
Learn More
Merck Serono Announce
July 30, 2012. Merck Serono announces the creation of the first spin-off company “Prexto ...
Learn More